(Reuters) -GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial, meeting its main goal. However, GSK said that the trial evaluating Zejula and Jemperli in first line […]
Health
GSK’s cancer drug combo meets main goal in ovarian cancer trial
Audio By Carbonatix
(Reuters) -GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial, meeting its main goal.
However, GSK said that the trial evaluating Zejula and Jemperli in first line advanced ovarian cancer failed to meet statistical significance in improving overall survival as a key secondary endpoint.
“As part of our focus in gynaecological cancers, we continue to evaluate the potential of this combination,” Hesham Abdullah, senior vice president, global head oncology, R&D at GSK, said in a statement.
The British drugmaker, which has been grappling with a decline in its vaccines businesses, has stepped up its efforts in cancer treatment in recent years, and is gearing up for five major new drug launches in 2025, including experimental cancer drug Blenrep.
“GSK remains trading at valuation lows, but with not too many catalysts on the near-term horizon, we find it hard to see what could drive a narrative shift,” Barclays analysts said in a fourth-quarter preview note.
(Reporting by Aby Jose Koilparambil and Yadarisa Shabong in Bengaluru; Editing by Mrigank Dhaniwala)